Pyoderma Gangrenosum in Patients with Palmoplantar Pustulosis Treated with Brodalumab: A Case Series

Brodalumab is approved for the treatment of palmoplantar pustulosis (PPP)—a chronic, immune-mediated skin disease—in Japan. A recent phase 3 randomized clinical trial and its open-label extension evaluated the long-term efficacy and safety of brodalumab over 68 weeks, in Japanese patients with PPP. This case series details the cases of pyoderma gangrenosum (PG), a rare, neutrophilic dermatosis, that were reported during the trial. Clinical and histopathological findings were reviewed for five patients with PPP who developed PG during or after brodalumab treatment in the phase 3 trial and its 68-week extension. All affected patients were female and aged 40–70 years without any other PG-associated medical conditions. Development of PG was observed at 61–345 days after treatment initiation. Brodalumab was discontinued after onset of PG, except in case 3. Prednisolone treatment was administered, except in case 4, with all cases showing improvement. PG may present as a rare condition in patients receiving brodalumab for PPP; the detailed mechanisms remain unclear, but early recognition and appropriate management is crucial. The open-label extension study was registered as NCT04061252.

Authors

Institutions

Publication Details

Journal
Dermatology and Therapy
Published
2026-11-15
DOI
https://doi.org/10.1007/s13555-026-01969-7
Primary Topic
Autoimmune and Inflammatory Disorders
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Pyoderma Gangrenosum in Patients with Palmoplantar Pustulosis Treated with Brodalumab: A Case Series

Ryoko Shimada‐Omori, Tadashi Terui, Yukari Okubo, Junichi Furuta et al.
Dermatology and Therapy
Autoimmune and Inflammatory Disorders
article

Pyoderma Gangrenosum in Patients with Palmoplantar Pustulosis Treated with Brodalumab: A Case Series

Ryoko Shimada‐Omori, Tadashi Terui, Yukari Okubo, Junichi Furuta, Masamoto Murakami, Satomi Kobayashi, Ryusuke Ono, Kenta Shishido, Maiko Kato, Taiki Udagawa
article en

Abstract

Brodalumab is approved for the treatment of palmoplantar pustulosis (PPP)—a chronic, immune-mediated skin disease—in Japan. A recent phase 3 randomized clinical trial and its open-label extension evaluated the long-term efficacy and safety of brodalumab over 68 weeks, in Japanese patients with PPP. This case series details the cases of pyoderma gangrenosum (PG), a rare, neutrophilic dermatosis, that were reported during the trial. Clinical and histopathological findings were reviewed for five patients with PPP who developed PG during or after brodalumab treatment in the phase 3 trial and its 68-week extension. All affected patients were female and aged 40–70 years without any other PG-associated medical conditions. Development of PG was observed at 61–345 days after treatment initiation. Brodalumab was discontinued after onset of PG, except in case 3. Prednisolone treatment was administered, except in case 4, with all cases showing improvement. PG may present as a rare condition in patients receiving brodalumab for PPP; the detailed mechanisms remain unclear, but early recognition and appropriate management is crucial. The open-label extension study was registered as NCT04061252.

Dermatology and Therapy
Nihon University (JP), University of Miyazaki (JP), University of Tsukuba (JP), Tokyo Medical University (JP), Tohoku University (JP), Kyowa Kirin (Japan) (JP), Osaka Minami Medical Center (JP), Kobe University (JP), Kindai University (JP)
Autoimmune and Inflammatory Disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon